The relative contribution of reversible β-cell dysfunction and a true decrease in β-cell mass during the onset of and progression of type 2 diabetes have been hotly debated ([@B1],[@B2]). Modest decreases in numbers of β-cells per islet and increases in β-cell apoptosis have been reported ([@B3]), but whether these are sufficient to account for the reduction in insulin secretory capacity remains unclear ([@B4]). Underpinned by recent rodent studies ([@B5]), a new hypothesis has been proposed whereby β-cell failure and increased α-cell function occur through dedifferentiation and reprogramming ([@B6]). We report, for the first time, expression of mesenchymal and α-cell phenotypic markers in human β-cells within intact islets of three individuals with diabetes.

RESEARCH DESIGN AND METHODS {#s1}
===========================

Ethical approval was acquired and informed consent was obtained from the patient or the family of the patient. In addition to patient samples, control pancreatic blocks and isolated islet sections were prepared from five deceased donors without diabetes (three women; age 24--61 years; BMI 25--34 kg/m^2^).

Tissue blocks and isolated islets were fixed in formalin and embedded in paraffin. Sections were stained with hematoxylin and eosin in addition to Sirius Red collagen staining using standard procedures.

Indirect immunofluorescence staining was performed on 4-μm sections after deparaffinization, rehydration, and heat-mediated antigen retrieval using citrate buffer. After blocking with 10% FCS, sections were incubated with guinea pig anti-insulin (1:500; Abcam, Cambridge, U.K.), rabbit antivimentin (1:250; Abcam), or mouse antiglucagon (1:1,000; Sigma-Aldrich, Gillingham, U.K.) overnight. Sections were incubated with anti-guinea pig fluorescein isothiocyanate, anti-mouse AF543, or anti-rabbit AF488/AF543 secondary antibodies (Invitrogen, Paisley, U.K.). For negative control subjects, primary antibody was replaced with appropriate serum. All sections were counterstained with 4′,6-diamidino-2-phenylindole.

RESULTS {#s2}
=======

Case reports {#s3}
------------

Patient 1 was a 65-year-old woman whose pancreas was procured during deceased organ donation after brain death after intracranial hemorrhage. Type 2 diabetes was diagnosed 15 months before death and was treated with metformin. Comorbid hypertension was treated with ramipril and hyperlipidemia was treated with simvastatin. BMI was 32 kg/m^2^, with random plasma glucose of 8.1 mmol/L.

Patient 2 was an 81-year-old woman who underwent distal pancreatectomy for an intraductal papillary mucinous neoplasm. She had experienced two episodes of pancreatitis 12 months and 7 years before pancreatic resection but had no chronic symptoms or evidence of pancreatic exocrine deficiency. Diabetes was diagnosed 17 months before surgery and treated with metformin. There were no other comorbidities and BMI was 25 kg/m^2^. Random plasma glucose was 7.5 mmol/L with HbA~1c~ of 72 mmol/mol (HbA~1c~ 8.7%).

Patient 3 was a 52-year-old woman whose pancreas was procured for clinical islet isolation during deceased organ donation after brain death after intracranial hemorrhage. There was no history of known diabetes, but a diagnostic HbA~1c~ test performed on admission indicated HbA~1c~ of 63 mmol/mol (HbA~1c~ 7.9%) with random glucose of 8.7 mmol/L. There were no other comorbidities, and BMI was 25 kg/m^2^.

### Patient 1. {#s4}

Morphological analysis after hematoxylin and eosin staining of pancreatic sections showed islet size, distribution, and integrity comparable with those of nondiabetic control subjects. There was no overt islet inflammatory cell infiltration in patient or control sections. There was no evidence of fibrosis in islets or exocrine pancreatic tissue with patterns of collagen deposition comparable with those of control samples on Sirius Red staining.

Immunofluorescence staining clearly demonstrated cells within intact islets expressing both insulin and vimentin in the cytoplasm. Representative images from the pancreatic tail are shown in [Fig. 1*A*--*D*](#F1){ref-type="fig"}. As shown, cells expressing insulin and vimentin were present in ∼40% of islets, constituting ∼5% of insulin-positive cells in affected islets. In cells expressing both phenotypic markers, confocal imaging confirmed coexpression within individual cells and maintained characteristic cytoplasmic insulin and filamentous vimentin staining patterns.

![Pancreatic phenotypic analysis of patient 1. Intraislet β-cells coexpressing the mesenchymal marker vimentin (*A--D*). The boxed area in *panel* *A* indicates the region that is magnified in *panels* *B--D*. Arrows indicate cells expressing both insulin (*B,C*) and vimentin (*B,D*). *E*: Cytofluorogram derived from this image confirming colocalization of insulin and vimentin in islet β-cells. Comparative cytofluorogram from stained, normal, nondiabetic pancreas (*F*) confirming no colocalization of insulin (green) and vimentin (red). *G--I*: Representative images show islet β-cells from patient 1 coexpressing the α-cell marker glucagon. The boxed area in panel *G* indicates the magnified region in panels *H* and *I*, with arrows indicating cells expressing both insulin (*H*) and glucagon (*I*). *J--L*: Intraislet cells coexpressing glucagon and vimentin. The boxed area in panel *J* indicates the region that is magnified in panels *K* and *L*. Arrows indicate cells expressing both glucagon (*K*) and vimentin (*L*).](3818fig1){#F1}

In contrast, no coexpression of vimentin in insulin-positive cells within or outside islets was detected in nondiabetic control sections. Cytofluorograms confirmed colocalization of both markers in patient 1 ([Fig. 1*E*](#F1){ref-type="fig"}) but confirmed absence of this mixed phenotype in control sections ([Fig. 1*F*](#F1){ref-type="fig"}).

Islet cells coexpressing insulin and glucagon within the cytoplasm were identified in pancreatic sections from patient 1 ([Fig. 1*G*--*I*](#F1){ref-type="fig"}). Coexpression of vimentin within glucagon-positive cells also was confirmed ([Fig. 1*J*--*L*](#F1){ref-type="fig"}). Both of these phenotypes were rare, constituting ∼1% of all islet cells. In contrast, neither of these mixed phenotypes could be detected on pancreatic sections from nondiabetic control subjects.

### Patient 2. {#s5}

Macroscopic examination of resected pancreatic tail demonstrated a cystic area with a maximum diameter of 8 mm. Staining of pancreatic sections confirmed intraductal papillary mucinous neoplasm without high-grade dysplasia or evidence of malignancy. There was evidence of lobular atrophy and granulomatous inflammation in the surrounding pancreas, but islet endocrine morphology was reported as being within normal limits.

Islets stained positive for insulin, with categorical evidence of cells coexpressing insulin and vimentin, insulin and glucagon, and vimentin and glucagon ([Supplementary Fig. 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-0705/-/DC1)) within the cytoplasm. As in patient 1, ∼5% of insulin-positive cells in affected islets coexpressed insulin and vimentin. In patient 2, although cells expressing only insulin, glucagon, or vimentin could be clearly identified, many cells coexpressed insulin and glucagon and vimentin and glucagon in virtually all islets.

### Patient 3. {#s6}

Immunofluorescence staining of isolated islets enabled clear differentiation of individual cells, particularly at the periphery. Cells coexpressing insulin and vimentin, insulin and glucagon, and vimentin and glucagon within the cytoplasm were identified ([Supplementary Fig. 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-0705/-/DC1)). Absence of any of these phenotypes in control islets isolated from nondiabetic donors was confirmed.

CONCLUSIONS {#s7}
===========

Consistent with a role for dedifferentiation in the pathogenesis of β-cell dysfunction in diabetes, we describe previously unreported coexpression of mesenchymal and α-cell phenotypic markers in insulin-positive cells in two patients with recently diagnosed noninsulin-requiring diabetes and in one patient with previously undiagnosed diabetes. Furthermore, coexpression of vimentin in islet glucagon-positive cells has been demonstrated.

It recently has been postulated from a series of β-cell fate-marking studies of transgenic mice that dedifferentiation is the primary mechanism underlying β-cell failure in nonautoimmune diabetes ([@B5]). Specifically, the investigators proposed that metabolic stress leads to activation of mesenchymal markers in endocrine cells, a phenomenon well described in human β-cells after establishment in adherent proliferative culture but not previously described in vivo in preclinical studies or in situ in humans ([@B7],[@B8]).

The lineage-tracing studies performed by Talchai et al. ([@B5]) demonstrated that a number of dedifferentiated β-cells undergo conversion to other endocrine phenotypes, leading them to suggest that β-cell reprogramming to α-cells may explain the apparent reciprocal association of insulinopenia with hyperglucagonemia in early type 2 diabetes ([@B9]). The presence of cells coexpressing glucagon and insulin in the patients reported here is in keeping with this hypothesis. We also detected cells expressing both glucagon and vimentin, a phenotype reported in the preclinical studies. Dedifferentiation of nonendocrine pancreas with coexpression of epithelial and mesenchymal markers has been recognized in human sections, with occasional cells coexpressing vimentin and glucagon within the ducts of patients with type 2 diabetes ([@B10]).

Our data provide circumstantial evidence for the recently reported phenomenon of β-cell dedifferentiation and possible reprogramming to α-cells in humans. Whether this process is reversible in vivo, contributing to the rapid recovery of β-cell function after calorie restriction or bariatric surgery, requires further study. If so, then this may provide a new target for the development of disease-modifying drugs that restore β-cell mass and function in type 2 and secondary diabetes through redifferentiation.

Supplementary Material
======================

###### Supplementary Data

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-0705/-/DC1>.
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